The Psychedelic Therapeutics Market Size is valued at 3.94 Billion in 2022 and is predicted to reach 13.29 Billion by the year 2031 at a 14.92 % CAGR during the forecast period for 2023-2031.
Psychedelic medicines are also referred to as hallucinogenic. Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences.
The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth.
In 2021, North America led the market. Major determinants, such as the increase in the frequency of depression and other mental diseases and the rapid advancement of research, are driving the market growth. The population's increased awareness of anxiety and mental health is anticipated to stimulate regional growth further. The Asia-Pacific region is anticipated to see a considerable growth rate over the projected period as a result of the growing awareness of mental diseases and the expansion of healthcare infrastructure.
Market Segmentation
The global psychedelic therapeutics market is segmented on the basis of Origin of Psychedelic Substance, Type of Psychedelic Substance, Target Therapeutic Area and region. Based on the Origin of Psychedelic Substance, the market is divided into Synthetic Substances and Natural Substances. On the basis of Type of Psychedelic Substance, the market is divided in to GHB, Ketamine, MDMA and Psilocybin.
On the basis of Target Therapeutic Area, the market is divided into Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders and Trauma. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
Competitive Landscape
Some major key players in the Psychedelic Therapeutics Market:
- Celon Pharma S.A.,
- MAPS Public Benefit,
- MindMed,
- Janssen Pharmaceuticals,
- iX Biopharma Ltd,
- Jazz Pharmaceutical,
- Avadel,
- Pharmaceuticals plc,
- NeuroRx, Inc.,
- Douglas Pharmaceuticals Limited,
- The Emmes,
- Company, LLC,
- CaaMTech,
- COMPASS Pathways plc,
- Eleusis Benefit Corporation,
- AWAKN Life Sciences Inc,
- Psilera Bioscience,
- Braxia Scientific Corp.,
- Mindset Pharma,
- BetterLife Pharma,
- Cybin,
- CB Therapeutics,
- Numinus Wellness,
- Mydecine Innovations Group,
- Optimi Health,
- PharmaTher,
- Field Trip Health,
- ATAI Life Sciences,
- GH Research,
- Seelos Therapeutics,
- Small Pharma,
- Bright Minds Biosciences,
- Incannex Health,
- PsyBio Therapeutics,
- Universal Ibogaine,
- Levitee Labs,
- Mind Cure Health,
- Novamind,
- Clearmind Medicine,
- MYND Life Science,
- Wesana Health,
- Psyched Wellness,
- HAVN Life Sciences,
- Tryp Therapeutics,
- Psyence Group,
- Silo Pharma,
- Core One Labs,
- M2Bio Sciences,
- Neonmind Biosciences,
- Delic Corp,
- Nova Mentis Life Science,
- Beckley Psytech,
- Delix Therapeutics,
- Diamond Therapeutics,
- Tactogen,
- Psygen Labs Inc.,
- Bexson Biomedical,
- Eleusis Biotech,
- Psilera Biosceince,
- Octarine Bio,
- Heading Health,
- MAPS Public Benefit Corporation (PBC),
- Aphrodite Health,
- Terran Biosciences,
- Mycrodose Therapeutics,
- Reset Pharma,
- Clerkenwell Health,
- Alvarius Pharmaceuticals,
- Ceruvia Lifesciences,
- Other Prominent Player.
Psychedelic Therapeutics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 3.94 Billion |
|
Revenue Forecast In 2031 |
USD 13.29 Billion |
|
Growth Rate CAGR |
CAGR of 14.92 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Billion and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Type of Psychedelic Substance, Origin of Psychedelic Substance, Target Therapeutic Area |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx, Inc., Douglas Pharmaceuticals Limited, The Emmes, Company, LLC, CaaMTech, COMPASS Pathways plc, Eleusis Benefit Corporation, AWAKN Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp., Mindset Pharma, BetterLife Pharma, Cybin, CB Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, PharmaTher, Field Trip Health, ATAI Life Sciences, GH Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences, Incannex Health, PsyBio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, MYND Life Science, Wesana Health, Psyched Wellness, HAVN Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc., Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, MAPS Public Benefit Corporation (PBC), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences, and Other Prominent Player. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
